mTOR
mTOR (mechanistic target of rapamycin kinase, also known as FRAP, FRAP1, RAFT1 and RAPT1) is a serine/threonine protein kinase that acts as a central regulator of cellular metabolism, growth and survival. It integrates signals from hormones, growth factors, nutrients, energy and stress. Browse Assay Genie's current range of mTOR research reagents below, or read on for the biology behind the target.
mTOR directly or indirectly regulates the phosphorylation of a very large number of proteins, and it does so as the catalytic subunit of two structurally and functionally distinct signalling complexes, mTORC1 and mTORC2. In response to nutrients, growth factors or amino acids, mTORC1 is recruited to the lysosome membrane. There it promotes protein, lipid and nucleotide synthesis by phosphorylating key regulators of mRNA translation and ribosome synthesis, including EIF4EBP1, RPS6KB1 and RPS6KB2. In parallel, mTORC1 suppresses catabolic pathways, negatively regulating autophagy through phosphorylation of ULK1, and it phosphorylates the MiT/TFE factors TFEB, TFE3 and MITF to retain them in the cytosol when nutrients are present.
mTORC2 is nutrient-insensitive and transduces growth factor signals to pathways involved in proliferation, cytoskeletal organisation, lipogenesis and anabolic output. It phosphorylates and activates AGC family kinases including AKT, PKC isoforms and SGK1, and it contributes to the full activation of AKT1 alongside PDPK1. The source annotation also links mTOR to osteoclastogenesis, insulin signalling and the circadian clock, where it influences period length and rhythm amplitude in the suprachasmatic nucleus and liver clocks.
The mTOR gene encodes a member of the PI3/PI4-kinase family, within the phosphatidylinositol 3-kinase-related kinase group, and the protein is localised to several membranes as well as the cytoplasm and nucleus. The name reflects its identification as the target of the FKBP12-rapamycin complex, which causes cell-cycle arrest and immunosuppression; earlier names include FK506 binding protein 12-rapamycin associated protein 1 (FRAP1). Inhibitors of mTOR are used as immunosuppressants in organ transplantation, and mutations in the gene are associated with Smith-Kingsmore syndrome and somatic focal cortical dysplasia type II.
mTORC1 senses amino acids, growth factors and energy status at the lysosome to control protein, lipid and nucleotide synthesis.
mTORC1 phosphorylates ULK1 and TFEB under nutrient sufficiency, making mTOR a key node for studying autophagy and lysosomal stress responses.
mTORC2 phosphorylates AKT, SGK1 and PKC, and mTORC1 feeds back on insulin receptor signalling through GRB10.
mTOR is the target of rapamycin-based immunosuppressants, and variants are linked to Smith-Kingsmore syndrome and focal cortical dysplasia type II.
mTOR is a serine/threonine kinase that regulates cell metabolism, growth and survival. As part of mTORC1 it promotes protein, lipid and nucleotide synthesis and inhibits autophagy; as part of mTORC2 it activates AKT, PKC and SGK1 and influences the actin cytoskeleton.
The gene symbol is MTOR, and aliases include FRAP, FRAP1, FRAP2, RAFT1 and RAPT1. Earlier names include FK506 binding protein 12-rapamycin associated protein 1 and mechanistic target of rapamycin (serine/threonine kinase). UniProt lists it as serine/threonine-protein kinase mTOR.
Mutations in the mTOR gene are associated with Smith-Kingsmore syndrome and somatic focal cortical dysplasia type II. Mouse and rat both carry an orthologous Mtor gene; check the datasheet of any product for its validated reactivity.
Components, substrates and pathway partners of mTORC1 and mTORC2 involved in growth, autophagy and insulin signalling.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P42345; product specifications from Assay Genie datasheets.